Apriss logo

Appriss Awarded Texas State Board of Pharmacy Contract for New Prescription Monitoring Solution

Print
| Source: Appriss

LOUISVILLE, Ky., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and healthcare, announced that the Texas State Board of Pharmacy (TSBP) has signed an agreement to adopt Appriss' Prescription Drug Monitoring Solution, PMP AWARxE, to improve patient safety, combat prescription drug abuse and drug diversion.

Prescription Monitoring Programs (PMPs) are state-run programs that track the distribution of narcotics and other prescriptions for federally controlled substances. PMP AWARxE provides access to mandatory pharmacy reporting and offers secure accessibility to data across state lines.

"Appriss is proud to support the TSBP in the promotion of patient safety," said Krishnan Sastry, Executive Vice President of Appriss. "There is a definite evolution of focus of the prescription monitoring programs from solely being a vehicle for surveillance and law enforcement to one that helps identify patients at risk for opioid abuse and finding them the help they need. PMPs can serve as a core foundation in that mission to improve patient safety and fight addiction."

The TSBP will implement the HIPAA-compliant PMP platform in the fall of 2016 and joins 24 other states in adopting an Appriss prescription monitoring solution nationally.

About Appriss

Appriss provides data-driven solutions to fulfill our mission of keeping communities safe and informed. Partnering with public safety, healthcare, and leading private and public companies, Appriss delivers solutions that prevent fraud, mitigate risk, fight crime, ensure compliance, increase public safety and save lives. Appriss' solutions are always backed by excellent customer support with technical agents in the US that are available to help 24x7x365.
For more information, visit www.appriss.com (http://www.appriss.com).

Kathy Sue Bennett
Marketing Manager
Appriss, Inc.